Nastech Pharmaceuticals Company Inc announced that it starting a Phase 2 clinical trial to evaluate its fast-acting Insulin Nasal Spray for patients with diabetes.
The trial will be conducted with 20 Type 2 diabetic patients and will evaluate different dosages as compared to Novolog and a placebo when administered prior to a meal. The objective is to achieve glycemic control without hypoglycemia.
"Nastech's Insulin Nasal Spray has the potential to offer a unique product profile for diabetic patients and their physicians compared to existing marketed products due to its rapid onset of action and patient friendly, non- invasive dosage form that we believe avoids the potential safety concerns of pulmonary delivery," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech.
[Source: PRNewsWire]
Comment Preview